Literature DB >> 12742324

Influence of patient age on the susceptibility patterns of Streptococcus pneumoniae isolates in North America (2000-2001): report from the SENTRY Antimicrobial Surveillance Program.

Ronald N Jones1, Douglas J Biedenbach, Mondell L Beach.   

Abstract

Risks of developing resistance in Streptococcus pneumoniae can be greatly influenced by antimicrobial use that is often dictated by patterns of prescribing at various patient ages. The results from the SENTRY Antimicrobial Surveillance Program (2000-2001; North America) were examined for differing susceptibility profiles (25 antimicrobials) indexed by five patient age groups. All MIC results were from reference methods performed in central laboratories. Pneumococcal resistance rates in the youngest patient group (0-5 years) were significantly (p < 0.05) higher for penicillin, other beta-lactams, macrolides, tetracyclines and trimethoprim/sulfamethoxazole. In contrast, fluoroquinolone resistance in S. pneumoniae was greatest in the patients >/= 65 years (1.4% resistance to gatifloxacin, levofloxacin and moxifloxacin), where use of this class has been escalating. Continued local and global surveillance of resistances in common respiratory tract pathogens such as S. pneumoniae appears to be prudent practice to guide effective chemotherapy.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12742324     DOI: 10.1016/s0732-8893(03)00015-4

Source DB:  PubMed          Journal:  Diagn Microbiol Infect Dis        ISSN: 0732-8893            Impact factor:   2.803


  6 in total

1.  Antimicrobial susceptibility of invasive Streptococcus pneumoniae isolates in Portugal over an 11-year period.

Authors:  Ricardo Dias; Deolinda Louro; Manuela Caniça
Journal:  Antimicrob Agents Chemother       Date:  2006-06       Impact factor: 5.191

2.  Antimicrobial susceptibility of invasive and lower respiratory tract isolates of Streptococcus pneumoniae, 1998 to 2007.

Authors:  Otto G Vanderkooi; Athena McConnell; Deirdre L Church; James D Kellner
Journal:  Can J Infect Dis Med Microbiol       Date:  2009       Impact factor: 2.471

3.  Pharmacodynamic evaluation of meropenem and cefotaxime for pediatric meningitis: a report from the OPTAMA program.

Authors:  Jennifer M Ellis; Joseph L Kuti; David P Nicolau
Journal:  Paediatr Drugs       Date:  2006       Impact factor: 3.022

Review 4.  Gatifloxacin: a review of its use in the treatment of bacterial infections in the US.

Authors:  Susan J Keam; Katherine F Croom; Gillian M Keating
Journal:  Drugs       Date:  2005       Impact factor: 9.546

5.  In vitro antimicrobial susceptibilities of Streptococcus pneumoniae clinical isolates obtained in Canada in 2002.

Authors:  Jeff Powis; Allison McGeer; Karen Green; Otto Vanderkooi; Karl Weiss; George Zhanel; Tony Mazzulli; Magdalena Kuhn; Deirdre Church; Ross Davidson; Kevin Forward; Daryl Hoban; Andrew Simor; Donald E Low
Journal:  Antimicrob Agents Chemother       Date:  2004-09       Impact factor: 5.191

Review 6.  Re-evaluation of the therapy of severe pneumonia caused by Streptococcus pneumoniae.

Authors:  Joseph F Plouffe; Daniel R Martin
Journal:  Infect Dis Clin North Am       Date:  2004-12       Impact factor: 5.982

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.